Recent News

• 04.24.2025 - Cidara Therapeutics to Report First Quarter 2025 Financial Results and Host Inaugural Quarterly Conference Call on May 8, 2025
• 04.24.2025 - Cidara Therapeutics to Report First Quarter 2025 Financial Results and Host Inaugural Quarterly Conference Call on May 8, 2025
• 04.01.2025 - Cidara Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
• 04.01.2025 - Cidara Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
• 04.01.2025 - Cidara Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference
• 04.01.2025 - Cidara Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference
• 03.19.2025 - Cidara Therapeutics to Participate in World Health Organization Meeting on H5N1 Influenza Preparedness and Response
• 03.19.2025 - Cidara Therapeutics to Participate in World Health Organization Meeting on H5N1 Influenza Preparedness and Response
• 03.18.2025 - Cidara Therapeutics Announces Two Presentations on CD388 in Influenza at International Conference on Antiviral Research (ICAR) 2025
• 03.18.2025 - Cidara Therapeutics Announces Two Presentations on CD388 in Influenza at International Conference on Antiviral Research (ICAR) 2025

Recent Filings

• 04.16.2025 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 04.15.2025 - PRE 14A Other preliminary proxy statements
• 04.02.2025 - 4 Statement of changes in beneficial ownership of securities
• 04.02.2025 - 4 Statement of changes in beneficial ownership of securities
• 03.13.2025 - 4 Statement of changes in beneficial ownership of securities
• 03.13.2025 - 4 Statement of changes in beneficial ownership of securities